184 related articles for article (PubMed ID: 11284449)
1. P-glycoprotein-mediated transport of digitoxin, alpha-methyldigoxin and beta-acetyldigoxin.
Pauli-Magnus C; Mürdter T; Godel A; Mettang T; Eichelbaum M; Klotz U; Fromm MF
Naunyn Schmiedebergs Arch Pharmacol; 2001 Mar; 363(3):337-43. PubMed ID: 11284449
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein.
Pauli-Magnus C; von Richter O; Burk O; Ziegler A; Mettang T; Eichelbaum M; Fromm MF
J Pharmacol Exp Ther; 2000 May; 293(2):376-82. PubMed ID: 10773005
[TBL] [Abstract][Full Text] [Related]
3. Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein.
Pauli-Magnus C; Rekersbrink S; Klotz U; Fromm MF
Naunyn Schmiedebergs Arch Pharmacol; 2001 Dec; 364(6):551-7. PubMed ID: 11770010
[TBL] [Abstract][Full Text] [Related]
4. Transport and epithelial secretion of the cardiac glycoside, digoxin, by human intestinal epithelial (Caco-2) cells.
Cavet ME; West M; Simmons NL
Br J Pharmacol; 1996 Jul; 118(6):1389-96. PubMed ID: 8832062
[TBL] [Abstract][Full Text] [Related]
5. Use of cholestyramine in three patients with beta-acetyldigoxin, beta-methyldigoxin and digitoxin intoxication.
Kuhlmann J
Int J Clin Pharmacol Ther Toxicol; 1984 Oct; 22(10):543-8. PubMed ID: 6511130
[TBL] [Abstract][Full Text] [Related]
6. Selective inhibition of human cytochrome P450 3A4 by N-[2(R)-hydroxy-1(S)-indanyl]-5-[2(S)-(1, 1-dimethylethylaminocarbonyl)-4-[(furo[2, 3-b]pyridin-5-yl)methyl]piperazin-1-yl]-4(S)-hydroxy-2(R)-phenylmethy lpentanamide and P-glycoprotein by valspodar in gene transfectant systems.
Kawahara I; Kato Y; Suzuki H; Achira M; Ito K; Crespi CL; Sugiyama Y
Drug Metab Dispos; 2000 Oct; 28(10):1238-43. PubMed ID: 10997946
[TBL] [Abstract][Full Text] [Related]
7. Creation of polarized cells coexpressing CYP3A4, NADPH cytochrome P450 reductase and MDR1/P-glycoprotein.
Brimer C; Dalton JT; Zhu Z; Schuetz J; Yasuda K; Vanin E; Relling MV; Lu Y; Schuetz EG
Pharm Res; 2000 Jul; 17(7):803-10. PubMed ID: 10990198
[TBL] [Abstract][Full Text] [Related]
8. Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein.
Wandel C; Kim R; Wood M; Wood A
Anesthesiology; 2002 Apr; 96(4):913-20. PubMed ID: 11964599
[TBL] [Abstract][Full Text] [Related]
9. [Pharmacokinetics of beta-methyldigoxin and beta-acetyldigoxin in patients with cirrhosis of the liver (author's transl)].
Rameis H; Bonelli J; Waginger H; Hruby K
Wien Klin Wochenschr; 1981 Oct; 93(18):572-6. PubMed ID: 7303703
[TBL] [Abstract][Full Text] [Related]
10. Role of P-glycoprotein in pharmacokinetics and drug interactions of digoxin and beta-methyldigoxin in rats.
Funakoshi S; Murakami T; Yumoto R; Kiribayashi Y; Takano M
J Pharm Sci; 2003 Jul; 92(7):1455-63. PubMed ID: 12820149
[TBL] [Abstract][Full Text] [Related]
11. Identification of budesonide and prednisone as substrates of the intestinal drug efflux pump P-glycoprotein.
Dilger K; Schwab M; Fromm MF
Inflamm Bowel Dis; 2004 Sep; 10(5):578-83. PubMed ID: 15472518
[TBL] [Abstract][Full Text] [Related]
12. P-glycoprotein mediates efflux transport of darunavir in human intestinal Caco-2 and ABCB1 gene-transfected renal LLC-PK1 cell lines.
Fujimoto H; Higuchi M; Watanabe H; Koh Y; Ghosh AK; Mitsuya H; Tanoue N; Hamada A; Saito H
Biol Pharm Bull; 2009 Sep; 32(9):1588-93. PubMed ID: 19721237
[TBL] [Abstract][Full Text] [Related]
13. Characterisation of (R/S)-propafenone and its metabolites as substrates and inhibitors of P-glycoprotein.
Bachmakov I; Rekersbrink S; Hofmann U; Eichelbaum M; Fromm MF
Naunyn Schmiedebergs Arch Pharmacol; 2005 Mar; 371(3):195-201. PubMed ID: 15900513
[TBL] [Abstract][Full Text] [Related]
14. Interactions of attention-deficit/hyperactivity disorder therapeutic agents with the efflux transporter P-glycoprotein.
Zhu HJ; Wang JS; Donovan JL; Jiang Y; Gibson BB; DeVane CL; Markowitz JS
Eur J Pharmacol; 2008 Jan; 578(2-3):148-58. PubMed ID: 17963743
[TBL] [Abstract][Full Text] [Related]
15. Role of p-glycoprotein inhibition for drug interactions: evidence from in vitro and pharmacoepidemiological studies.
Eberl S; Renner B; Neubert A; Reisig M; Bachmakov I; König J; Dörje F; Mürdter TE; Ackermann A; Dormann H; Gassmann KG; Hahn EG; Zierhut S; Brune K; Fromm MF
Clin Pharmacokinet; 2007; 46(12):1039-49. PubMed ID: 18027988
[TBL] [Abstract][Full Text] [Related]
16. Digoxin concentration in cerebrospinal fluid-a study carried out after 9 days of treatment of beta-methyldigoxin or beta-acetyldigoxin.
Bonelli J; Rameis H; Waginger H
Int J Clin Pharmacol Ther Toxicol; 1981 Mar; 19(3):93-5. PubMed ID: 7228456
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [seecomments].
Fromm MF; Kim RB; Stein CM; Wilkinson GR; Roden DM
Circulation; 1999 Feb; 99(4):552-7. PubMed ID: 9927403
[TBL] [Abstract][Full Text] [Related]
18. [Determinants of plasma digoxin and digitoxin concentrations in elderly patients. A multivariate analysis].
Koenig W; Rietbrock N; Woodcock BG; Lehmacher W
Klin Wochenschr; 1987 Nov; 65(22):1073-80. PubMed ID: 3695294
[TBL] [Abstract][Full Text] [Related]
19. Phorbol 12-myristate 13-acetate inhibits P-glycoprotein-mediated efflux of digoxin in MDCKII-MDR1 and Caco-2 cell monolayer models.
Li YH; Bi HC; Huang L; Jin J; Zhong GP; Zhou XN; Huang M
Acta Pharmacol Sin; 2014 Feb; 35(2):283-91. PubMed ID: 24362330
[TBL] [Abstract][Full Text] [Related]
20. Impact of ABCB1 (MDR1) gene polymorphism and P-glycoprotein inhibitors on digoxin serum concentration in congestive heart failure patients.
Kurzawski M; Bartnicka L; Florczak M; Górnik W; Droździk M
Pharmacol Rep; 2007; 59(1):107-11. PubMed ID: 17377214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
